Core Viewpoint - Auna SA is identified as a promising investment opportunity, particularly as analysts project significant upside potential due to its growth strategies and market positioning [1][2]. Group 1: Company Overview - Auna SA operates a vertically integrated network of healthcare facilities, including hospitals, clinics, and outpatient services across Peru, Colombia, and Mexico, with a focus on high-complexity care, especially in oncology and prepaid health plans [4]. - The company is currently trading at a low valuation of 4.5 times its estimated adjusted earnings for 2026, indicating potential for significant price appreciation [1]. Group 2: Growth Drivers - Auna's growth is expected to accelerate due to the expansion of its operations in Mexico, supported by a $500 million investment from Sojitz and the Trecca PPP project in Peru [2][3]. - The healthcare spending increase in Latin America is anticipated to benefit Auna, with strong growth reported in Peru and Colombia, which helped mitigate declines in Mexico [3]. Group 3: Market Context - The Latin American healthcare market is characterized by low penetration of private insurance, covering only about 10% of the population, presenting a substantial growth opportunity for Auna [2].

Industry Overview - Small-cap and penny stocks are experiencing a notable rally, with the Russell 2000 index up by over 5%, significantly outperforming the S&P 500, which is up by only 1.7% [1] - The rally is driven by expectations of market-beating results from these companies, which are trading at discounted valuations [1][2] - The Federal Reserve's anticipated monetary policy easing is further supporting the case for investing in penny and small-cap stocks [2] January Effect - The January effect is benefiting small-cap companies as investors are buying smaller stocks, particularly those that faced tax-loss selling in the previous quarter [3] - The Russell 2000 index has shown strong performance in January, suggesting potential continued strength into February [3] Fundamentals and Valuations - Fundamentals for small-cap companies are improving, with their 1-year price-to-earnings multiples being 30% lower than those of large-cap companies [4] - Small caps have shown earnings growth that slightly exceeded larger companies for the first time in thirteen quarters [4] Seasonal Trends - Historically, small caps perform better in midterm election years, averaging a 1.3% advance in February compared to the S&P 500's average of 0.3% [5] - Current seasonal patterns indicate a hawkish bias towards interest rates, favoring small-cap stocks [5] Investment Opportunities - The S&P SmallCap 600 index is already up by more than 5% for the year, indicating a favorable environment for investing in penny stocks trading under $5 [6] - A list of 14 NYSE penny stocks has been compiled based on popularity among hedge funds and potential upside of over 30% [8][9] Company Highlights - **Nouveau Monde Graphite Inc. (NYSE:NMG)**: Current share price is $2.09 with an upside potential of 107.33%. The company has a net asset value of $919 million or $3.51 per share, factoring in a cash balance of $68.8 million and debt of $11.6 million [11][12]. It has signed a 7-year off-take agreement with the Canadian government for 30,000 tons per annum of graphite concentrate [13][14]. - **Auna SA (NYSE:AUNA)**: Current share price is $4.76 with an upside potential of 53.36%. Analysts expect significant growth due to a $500 million expansion in Mexico and a strategic partnership with Sojitz [15][16][17]. The company operates a vertically integrated network of healthcare facilities in Latin America, focusing on high-complexity care [18].

Core Insights - AUNA has shown a modest gain of 0.43% over the past month, but a decline of 4.93% in the last 10 days may present a buying opportunity for investors [1][6] - The stock has a forecasted increase of 94.38%, indicating significant growth potential and making it attractive for growth-oriented investors [2][6] - AUNA's financial health is strong, evidenced by a Piotroski Score of 8, which suggests robust financials and efficient operations [3][6] - The recent local minimum touched by AUNA could signal a potential turnaround, enhancing its appeal for investors [4] - With a target price of $9, AUNA offers significant upside potential from current levels, making it a promising investment opportunity [5]

Group 1 - Auna SA (NYSE:AUNA) is recognized as one of the 10 Best New Penny Stocks to Invest In, with Morgan Stanley lowering its price target from $11.50 to $10 while maintaining an Overweight rating [1] - By the end of Q3 2025, Auna SA's network will include 31 healthcare facilities, comprising 2,333 beds and approximately 1.4 million healthcare plans [2] - Auna SA generates strong operating cash flow, enabling the company to reduce its debt levels over time [3] Group 2 - Auna SA's strategy focuses on expanding into markets with low-priced healthcare policies, particularly in Peru and Mexico, where private healthcare access is limited [3][4] - The company is a leading healthcare provider in Latin America, operating hospitals and clinics while offering health plans that prioritize prevention and high-complexity care [4] - The growth potential in Mexico is significant, requiring minimal capital expenditure for occupancy of existing beds [1][3]

Core Insights - Surgery Partners (SGRY) reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share, and down from $0.19 per share a year ago, representing an earnings surprise of -31.58% [1] - The company posted revenues of $821.5 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.31%, but up from $770.4 million year-over-year [2] - The stock has added about 1.6% since the beginning of the year, underperforming the S&P 500's gain of 14.4% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is $0.46 on revenues of $940.87 million, and for the current fiscal year, it is $0.92 on revenues of $3.36 billion [7] - The estimate revisions trend for Surgery Partners was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Surgery Partners belongs, is currently in the top 38% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Another company in the same industry, Auna S.A. (AUNA), is expected to report quarterly earnings of $0.20 per share, reflecting a year-over-year change of -23.1%, with revenues expected to be $330.33 million, up 8.7% from the previous year [9]

Core Insights - Astrana Health, Inc. reported quarterly earnings of $0.01 per share, significantly missing the Zacks Consensus Estimate of $0.47 per share, representing an earnings surprise of -97.87% [1] - The company posted revenues of $956.05 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.61%, and showing a substantial increase from $478.71 million year-over-year [2] - Astrana Health, Inc. has not surpassed consensus EPS estimates over the last four quarters, indicating a trend of underperformance in earnings expectations [2] Financial Performance - The earnings for the previous year were $0.33 per share, highlighting a decline in earnings year-over-year [1] - The company has topped consensus revenue estimates three times in the last four quarters, indicating some strength in revenue generation despite the earnings miss [2] - The current consensus EPS estimate for the upcoming quarter is $0.45 on revenues of $978.65 million, and for the current fiscal year, it is $1.24 on revenues of $3.2 billion [7] Market Position - Astrana Health, Inc. shares have increased by approximately 5.4% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.6% [3] - The Zacks Rank for Astrana Health, Inc. is currently 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] - The Medical - Outpatient and Home Healthcare industry, to which Astrana Health belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Company Overview - Sonida Senior Living (SNDA) shares increased by 14.7% to $29.52, with a higher-than-average trading volume, contrasting with a 3.3% loss over the past four weeks [1][2] Acquisition Announcement - Sonida announced the acquisition of 100% of CNL Healthcare Properties, Inc. in a cash and stock deal valued at approximately $1.8 billion, expected to close in late Q1 or early Q2 of 2026, pending customary closing conditions [2] Financial Performance Expectations - The company is projected to report a quarterly loss of $0.75 per share, reflecting a year-over-year increase of 23.5%, with revenues anticipated at $85.34 million, up 14.2% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Sonida operates within the Zacks Medical Services industry, where another company, Auna S.A. (AUNA), experienced a 3% decline to $5.43 and has returned -15.3% over the past month [4] - Auna S.A.'s consensus EPS estimate has also remained unchanged at $0.2, representing a year-over-year decline of 23.1% [5]

分组1 - Enhabit reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.07 per share a year ago, resulting in an earnings surprise of +30.00% [1] - The company posted revenues of $266.1 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.14%, and showing an increase from $260.6 million year-over-year [2] - Enhabit shares have underperformed the market, losing about 14.3% since the beginning of the year compared to the S&P 500's gain of 7.1% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.11 on revenues of $266.82 million, and for the current fiscal year, it is $0.44 on revenues of $1.06 billion [7] - The Medical Services industry, to which Enhabit belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Auna S.A., another company in the same industry, is expected to report quarterly earnings of $0.16 per share, reflecting a year-over-year change of +433.3%, with revenues expected to be $314.67 million, up 7.8% from the previous year [9]

Company Performance - RenovoRx, Inc. reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.07 per share a year ago [1] - The company posted revenues of $0.2 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.50%, and this is an increase from zero revenues a year ago [2] - RenovoRx shares have declined approximately 18.6% since the beginning of the year, while the S&P 500 has gained 0.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.32 million, and for the current fiscal year, it is -$0.30 on revenues of $1.55 million [7] - The estimate revisions trend for RenovoRx is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which RenovoRx belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Viatris (VTRS) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.04%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.57 per share when it actually produced earnings of $0.54, delivering a surprise of -5.26%.Over the last four quarters, the company ...